长春瑞滨联合顺铂(NP)治疗晚期非小细胞肺癌的疗效及生存因素分析

Efficacy and analysis of survival associated factors of navelbine and cisplatin chemotheraphy on advanced non-small-cell lung cancer

目的分析长春瑞滨（NVB）联合顺铂治疗晚期非小细胞肺癌（NSCLC）患者的临床疗效及预后相关性生存因素。方法 59例经病理或细胞学证实的Ⅲb~Ⅳ期晚期NSCLC患者均接受长春瑞滨联合顺铂（NP）治疗方案,服药前及服药后每2~3周进行疗效及全身评估。结果 59例NSCLC患者完全缓解6例（10.17%）、部分缓解17例（28.81%）、稳定19例（32.20%）、进展18例（30.51%）,总有效率38.98%。中位总生存期14.9个月,无治疗相关性死亡。结论长春瑞滨（NVB）联合顺铂对晚期非小细胞肺癌有较好临床疗效,和患者的预后相关性生存因素密切相关。因此,长春瑞滨（NVB）联合顺铂可作为晚期NSCLC的较有效治疗方案。

Objective To evaluate the efficacy of navelbine and cisplatin chemotherapy on advanced non-small-cell lung cancer and analyze survival associated factors.Methods A total of 59 cases of stage Ⅲb～ⅣNSCLC confirmed by pathological and cytological examination were treated by chemotherapy of navelbine and cisplatin.Efficacy and whole body condition were evaluated before and every 2～3 weeks after administration of erlotinib.Results In 59 patients with NSCLC,6 cases（10.17%）were complete remission,17 cases（28.81%） partly remission,19 cases（32.20%）stable,and 18 cases（30.51%）progressed.The total effective rate was 38.98%.The median survival time was 14.9 months.There were no treatment-related deaths.Conclusion The chemotherapy of navelbine and cisplatin for advanced non-small-cell lung cancer has good clinical effect,and is closely related to survival factors of the prognosis of patients.Therefore,the chemotherapy of navelbine and cisplatin can be considered as an effective treatment for advanced-stage NSCLC.